Ceftazidime-Avibactam Concentrations in Critically Ill Patients with Renal Failure on CVVHDF

This study focuses on critically ill patients with renal failure who need a treatment called continuous venovenous hemodiafiltration (CVVHDF). These patients are also prescribed a medication named Ceftazidime-Avibactam to treat their infection. The main goal is to understand how this drug behaves in their bodies, particularly in the blood and dialysis fluid. The study is important as it helps determine if the usual dose of Ceftazidime-Avibactam is suitable for such patients, potentially improving their care and addressing the challenges associated with their condition. During the study, researchers measure the levels of Ceftazidime-Avibactam in both the patients' blood and the fluid removed during CVVHDF. This helps them evaluate how the drug moves through the body when it's filtering blood. The study assesses if the drug reaches certain targets, which indicate its effectiveness. By examining these concentrations, the study provides insights into the drug's behavior in critically ill patients with renal failure undergoing CVVHDF.